Mitochondrial myopathies

M. Zeviani, P. Amati, A. Savoia

Research output: Contribution to journalArticle

Abstract

Major new advances in the genetic and biochemical characterization of mitochondrial myopathies are discussed, within a general presentation of this important new area of human pathology. Mitochondrial disorders can be due to mutations in either nuclear or mitochondrial genes involved in the synthesis of individual respiratory chain subunits or in their posttranslational control. Although no mutations of nuclear-encoded oxidative phosphorylation subunits have been reported so far in humans, numerous biochemically defined disorders are attributed to nuclear gene defects. In contrast, molecular lesions of mitochondrial DNA are recognized as an increasingly frequent cause of defective oxidative phosphorylation. Numerous new mutations recently have been identified, including both maternally inherited point mutations and sporadic large-scale rearrangements. In addition, the identification of new or overlap syndromes has substantially broadened the clinical spectrum of mitochondrial disorders. To gain insight into the pathogenesis of these disorders, the relationship between specific clinical presentations and the mitochondrial genotype has been intensively investigated. In most cases, the phenotypic expression of the mitochondrial DNA mutations depends on the interplay among the relative amount of mutated vs wild-type genomes, ie, the degree of mitochondrial heteroplasmy and its tissue and cell distribution, the reliance of the affected tissues on aerobic energy supply, the age and gender of the individual, and other still poorly understood factors including individual 'nuclear genetic background' and environmental factors.

Original languageEnglish
Pages (from-to)559-567
Number of pages9
JournalCurrent Opinion in Rheumatology
Volume6
Issue number6
Publication statusPublished - 1994

Fingerprint

Mitochondrial Myopathies
Mitochondrial Diseases
Mutation
Oxidative Phosphorylation
Mitochondrial DNA
Mitochondrial Genes
Tissue Distribution
Electron Transport
Point Mutation
Molecular Biology
Genotype
Genome
Pathology
Genes

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Zeviani, M., Amati, P., & Savoia, A. (1994). Mitochondrial myopathies. Current Opinion in Rheumatology, 6(6), 559-567.

Mitochondrial myopathies. / Zeviani, M.; Amati, P.; Savoia, A.

In: Current Opinion in Rheumatology, Vol. 6, No. 6, 1994, p. 559-567.

Research output: Contribution to journalArticle

Zeviani, M, Amati, P & Savoia, A 1994, 'Mitochondrial myopathies', Current Opinion in Rheumatology, vol. 6, no. 6, pp. 559-567.
Zeviani, M. ; Amati, P. ; Savoia, A. / Mitochondrial myopathies. In: Current Opinion in Rheumatology. 1994 ; Vol. 6, No. 6. pp. 559-567.
@article{24c8f28eab194dcba37bf32c24c346e4,
title = "Mitochondrial myopathies",
abstract = "Major new advances in the genetic and biochemical characterization of mitochondrial myopathies are discussed, within a general presentation of this important new area of human pathology. Mitochondrial disorders can be due to mutations in either nuclear or mitochondrial genes involved in the synthesis of individual respiratory chain subunits or in their posttranslational control. Although no mutations of nuclear-encoded oxidative phosphorylation subunits have been reported so far in humans, numerous biochemically defined disorders are attributed to nuclear gene defects. In contrast, molecular lesions of mitochondrial DNA are recognized as an increasingly frequent cause of defective oxidative phosphorylation. Numerous new mutations recently have been identified, including both maternally inherited point mutations and sporadic large-scale rearrangements. In addition, the identification of new or overlap syndromes has substantially broadened the clinical spectrum of mitochondrial disorders. To gain insight into the pathogenesis of these disorders, the relationship between specific clinical presentations and the mitochondrial genotype has been intensively investigated. In most cases, the phenotypic expression of the mitochondrial DNA mutations depends on the interplay among the relative amount of mutated vs wild-type genomes, ie, the degree of mitochondrial heteroplasmy and its tissue and cell distribution, the reliance of the affected tissues on aerobic energy supply, the age and gender of the individual, and other still poorly understood factors including individual 'nuclear genetic background' and environmental factors.",
author = "M. Zeviani and P. Amati and A. Savoia",
year = "1994",
language = "English",
volume = "6",
pages = "559--567",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Mitochondrial myopathies

AU - Zeviani, M.

AU - Amati, P.

AU - Savoia, A.

PY - 1994

Y1 - 1994

N2 - Major new advances in the genetic and biochemical characterization of mitochondrial myopathies are discussed, within a general presentation of this important new area of human pathology. Mitochondrial disorders can be due to mutations in either nuclear or mitochondrial genes involved in the synthesis of individual respiratory chain subunits or in their posttranslational control. Although no mutations of nuclear-encoded oxidative phosphorylation subunits have been reported so far in humans, numerous biochemically defined disorders are attributed to nuclear gene defects. In contrast, molecular lesions of mitochondrial DNA are recognized as an increasingly frequent cause of defective oxidative phosphorylation. Numerous new mutations recently have been identified, including both maternally inherited point mutations and sporadic large-scale rearrangements. In addition, the identification of new or overlap syndromes has substantially broadened the clinical spectrum of mitochondrial disorders. To gain insight into the pathogenesis of these disorders, the relationship between specific clinical presentations and the mitochondrial genotype has been intensively investigated. In most cases, the phenotypic expression of the mitochondrial DNA mutations depends on the interplay among the relative amount of mutated vs wild-type genomes, ie, the degree of mitochondrial heteroplasmy and its tissue and cell distribution, the reliance of the affected tissues on aerobic energy supply, the age and gender of the individual, and other still poorly understood factors including individual 'nuclear genetic background' and environmental factors.

AB - Major new advances in the genetic and biochemical characterization of mitochondrial myopathies are discussed, within a general presentation of this important new area of human pathology. Mitochondrial disorders can be due to mutations in either nuclear or mitochondrial genes involved in the synthesis of individual respiratory chain subunits or in their posttranslational control. Although no mutations of nuclear-encoded oxidative phosphorylation subunits have been reported so far in humans, numerous biochemically defined disorders are attributed to nuclear gene defects. In contrast, molecular lesions of mitochondrial DNA are recognized as an increasingly frequent cause of defective oxidative phosphorylation. Numerous new mutations recently have been identified, including both maternally inherited point mutations and sporadic large-scale rearrangements. In addition, the identification of new or overlap syndromes has substantially broadened the clinical spectrum of mitochondrial disorders. To gain insight into the pathogenesis of these disorders, the relationship between specific clinical presentations and the mitochondrial genotype has been intensively investigated. In most cases, the phenotypic expression of the mitochondrial DNA mutations depends on the interplay among the relative amount of mutated vs wild-type genomes, ie, the degree of mitochondrial heteroplasmy and its tissue and cell distribution, the reliance of the affected tissues on aerobic energy supply, the age and gender of the individual, and other still poorly understood factors including individual 'nuclear genetic background' and environmental factors.

UR - http://www.scopus.com/inward/record.url?scp=0028062988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028062988&partnerID=8YFLogxK

M3 - Article

C2 - 7865374

AN - SCOPUS:0028062988

VL - 6

SP - 559

EP - 567

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 6

ER -